These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16791286)

  • 1. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
    Hoffmann D; Bangen JM; Bayer W; Wildner O
    Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
    Hoffmann D; Wildner O
    Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
    Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
    Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
    Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
    Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
    Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
    Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
    Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
    J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy.
    Hoffmann D; Grunwald T; Kuate S; Wildner O
    Cancer Biol Ther; 2007 Apr; 6(4):510-8. PubMed ID: 17374986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy.
    Hoffmann D; Wildner O
    Mol Cancer Ther; 2006 Aug; 5(8):2013-22. PubMed ID: 16928822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
    Hoffmann D; Bayer W; Wildner O
    Hum Gene Ther; 2007 May; 18(5):435-50. PubMed ID: 17518612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
    Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.
    Liu XY; Qiu SB; Zou WG; Pei ZF; Gu JF; Luo CX; Ruan HM; Chen Y; Qi YP; Qian C
    Mol Ther; 2005 Apr; 11(4):531-41. PubMed ID: 15771956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.
    Yoo JY; Kim JH; Kim J; Huang JH; Zhang SN; Kang YA; Kim H; Yun CO
    Gene Ther; 2008 May; 15(9):635-51. PubMed ID: 18273054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.
    Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
    Gene Ther; 2006 Aug; 13(16):1235-43. PubMed ID: 16617300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
    Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
    Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
    Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.
    Dong YB; Yang HL; McMasters KM
    Cancer Gene Ther; 2003 Mar; 10(3):168-78. PubMed ID: 12637937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
    Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
    Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.